Urgent.News

600+ sources. One page. See who else covered it.

Editions

Health & Medicine

Capricor, seeking lifeline for Duchenne therapy, says it will ask FDA to review additional data

After a negative FDA advisory committee vote, Capricor Therapeutics said it will file additional data and analyses on its Duchenne muscular dystrophy therapy in hopes of a better shot at potential approval in a narrower ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Friday 14 August →